Cargando…
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. However, there is still considerable overtreatment and als...
Autores principales: | van den Heerik, Anne Sophie V M, Horeweg, Nanda, Nout, Remi A, Lutgens, Ludy C H W, van der Steen-Banasik, Elzbieta M, Westerveld, G Henrike, van den Berg, Hetty A, Slot, Annerie, Koppe, Friederike L A, Kommoss, Stefan, Mens, Jan Willem M, Nowee, Marlies E, Bijmolt, Stefan, Cibula, David, Stam, Tanja C, Jurgenliemk-Schulz, Ina M, Snyers, An, Hamann, Moritz, Zwanenburg, Aleida G, Coen, Veronique L M A, Vandecasteele, Katrien, Gillham, Charles, Chargari, Cyrus, Verhoeven-Adema, Karen W, Putter, Hein, van den Hout, Wilbert B, Wortman, Bastiaan G, Nijman, Hans W, Bosse, Tjalling, Creutzberg, Carien L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788476/ https://www.ncbi.nlm.nih.gov/pubmed/33046573 http://dx.doi.org/10.1136/ijgc-2020-001929 |
Ejemplares similares
-
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
por: Horeweg, Nanda, et al.
Publicado: (2023) -
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
por: Wortman, B. G., et al.
Publicado: (2018) -
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2021) -
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
por: de Boer, S M, et al.
Publicado: (2018) -
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
por: León-Castillo, Alicia, et al.
Publicado: (2020)